News Digging > Featured > Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study,Tisagenlecleucel (tisa-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy first approved by the US food and drug administration in 2017 for relapsed or refractory...

Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study

Tisagenlecleucel (tisa-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy first approved by the US food and drug administration in 2017 for relapsed or refractory…